Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is projected to release its Q4 2024 earnings data before the market opens on Tuesday, March 11th. Analysts expect Achieve Life Sciences to post earnings of ($0.30) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Stock Performance
Shares of NASDAQ:ACHV traded up $0.00 on Thursday, reaching $2.65. 184,764 shares of the company's stock were exchanged, compared to its average volume of 255,455. Achieve Life Sciences has a twelve month low of $2.59 and a twelve month high of $5.59. The company has a fifty day moving average of $3.20 and a 200-day moving average of $4.04. The company has a market capitalization of $91.27 million, a price-to-earnings ratio of -2.35 and a beta of 1.67. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on ACHV. RODMAN&RENSHAW raised Achieve Life Sciences to a "strong-buy" rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on Achieve Life Sciences in a research note on Thursday, November 14th. They issued a "buy" rating and a $12.00 price target for the company. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $15.75.
View Our Latest Analysis on ACHV
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Recommended Stories

Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.